283 related articles for article (PubMed ID: 20397705)
1. Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors.
Beria I; Ballinari D; Bertrand JA; Borghi D; Bossi RT; Brasca MG; Cappella P; Caruso M; Ceccarelli W; Ciavolella A; Cristiani C; Croci V; De Ponti A; Fachin G; Ferguson RD; Lansen J; Moll JK; Pesenti E; Posteri H; Perego R; Rocchetti M; Storici P; Volpi D; Valsasina B
J Med Chem; 2010 May; 53(9):3532-51. PubMed ID: 20397705
[TBL] [Abstract][Full Text] [Related]
2. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.
Beria I; Bossi RT; Brasca MG; Caruso M; Ceccarelli W; Fachin G; Fasolini M; Forte B; Fiorentini F; Pesenti E; Pezzetta D; Posteri H; Scolaro A; Re Depaolini S; Valsasina B
Bioorg Med Chem Lett; 2011 May; 21(10):2969-74. PubMed ID: 21470862
[TBL] [Abstract][Full Text] [Related]
3. 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazolines as potent and selective Polo-like kinase 1 (PLK1) inhibitors.
Beria I; Valsasina B; Brasca MG; Ceccarelli W; Colombo M; Cribioli S; Fachin G; Ferguson RD; Fiorentini F; Gianellini LM; Giorgini ML; Moll JK; Posteri H; Pezzetta D; Roletto F; Sola F; Tesei D; Caruso M
Bioorg Med Chem Lett; 2010 Nov; 20(22):6489-94. PubMed ID: 20932759
[TBL] [Abstract][Full Text] [Related]
4. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
Sato Y; Onozaki Y; Sugimoto T; Kurihara H; Kamijo K; Kadowaki C; Tsujino T; Watanabe A; Otsuki S; Mitsuya M; Iida M; Haze K; Machida T; Nakatsuru Y; Komatani H; Kotani H; Iwasawa Y
Bioorg Med Chem Lett; 2009 Aug; 19(16):4673-8. PubMed ID: 19589677
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and SAR of new pyrazolo[4,3-h]quinazoline-3-carboxamide derivatives as potent and selective MPS1 kinase inhibitors.
Caldarelli M; Angiolini M; Disingrini T; Donati D; Guanci M; Nuvoloni S; Posteri H; Quartieri F; Silvagni M; Colombo R
Bioorg Med Chem Lett; 2011 Aug; 21(15):4507-11. PubMed ID: 21723120
[TBL] [Abstract][Full Text] [Related]
6. Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.
Brasca MG; Amboldi N; Ballinari D; Cameron A; Casale E; Cervi G; Colombo M; Colotta F; Croci V; D'Alessio R; Fiorentini F; Isacchi A; Mercurio C; Moretti W; Panzeri A; Pastori W; Pevarello P; Quartieri F; Roletto F; Traquandi G; Vianello P; Vulpetti A; Ciomei M
J Med Chem; 2009 Aug; 52(16):5152-63. PubMed ID: 19603809
[TBL] [Abstract][Full Text] [Related]
7. Phosphopeptides with improved cellular uptake properties as ligands for the polo-box domain of polo-like kinase 1.
Richter S; Neundorf I; Loebner K; Gräber M; Berg T; Bergmann R; Steinbach J; Pietzsch J; Wuest F
Bioorg Med Chem Lett; 2011 Aug; 21(16):4686-9. PubMed ID: 21778054
[TBL] [Abstract][Full Text] [Related]
8. Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.
Rheault TR; Donaldson KH; Badiang-Alberti JG; Davis-Ward RG; Andrews CW; Bambal R; Jackson JR; Cheung M
Bioorg Med Chem Lett; 2010 Aug; 20(15):4587-92. PubMed ID: 20594842
[TBL] [Abstract][Full Text] [Related]
9. Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.
Zhang Q; Xia Z; Mitten MJ; Lasko LM; Klinghofer V; Bouska J; Johnson EF; Penning TD; Luo Y; Giranda VL; Shoemaker AR; Stewart KD; Djuric SW; Vasudevan A
Bioorg Med Chem Lett; 2012 Dec; 22(24):7615-22. PubMed ID: 23103095
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel polo-like kinase 1 inhibitors by a hybrid virtual screening.
Lu S; Sun SL; Liu HC; Chen YD; Yuan HL; Gao YP; Yang P; Lu T
Chem Biol Drug Des; 2012 Aug; 80(2):328-39. PubMed ID: 22583481
[TBL] [Abstract][Full Text] [Related]
11. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.
Gilmartin AG; Bleam MR; Richter MC; Erskine SG; Kruger RG; Madden L; Hassler DF; Smith GK; Gontarek RR; Courtney MP; Sutton D; Diamond MA; Jackson JR; Laquerre SG
Cancer Res; 2009 Sep; 69(17):6969-77. PubMed ID: 19690138
[TBL] [Abstract][Full Text] [Related]
12. First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery.
Menichincheri M; Bargiotti A; Berthelsen J; Bertrand JA; Bossi R; Ciavolella A; Cirla A; Cristiani C; Croci V; D'Alessio R; Fasolini M; Fiorentini F; Forte B; Isacchi A; Martina K; Molinari A; Montagnoli A; Orsini P; Orzi F; Pesenti E; Pezzetta D; Pillan A; Poggesi I; Roletto F; Scolaro A; Tatò M; Tibolla M; Valsasina B; Varasi M; Volpi D; Santocanale C; Vanotti E
J Med Chem; 2009 Jan; 52(2):293-307. PubMed ID: 19115845
[TBL] [Abstract][Full Text] [Related]
13. Selectivity-determining residues in Plk1.
Kothe M; Kohls D; Low S; Coli R; Rennie GR; Feru F; Kuhn C; Ding YH
Chem Biol Drug Des; 2007 Dec; 70(6):540-6. PubMed ID: 18005335
[TBL] [Abstract][Full Text] [Related]
14. 5-(2-amino-pyrimidin-4-yl)-1H-pyrrole and 2-(2-amino-pyrimidin-4-yl)-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one derivatives as new classes of selective and orally available Polo-like kinase 1 inhibitors.
Caruso M; Valsasina B; Ballinari D; Bertrand J; Brasca MG; Caldarelli M; Cappella P; Fiorentini F; Gianellini LM; Scolaro A; Beria I
Bioorg Med Chem Lett; 2012 Jan; 22(1):96-101. PubMed ID: 22154349
[TBL] [Abstract][Full Text] [Related]
15. Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.
Traquandi G; Ciomei M; Ballinari D; Casale E; Colombo N; Croci V; Fiorentini F; Isacchi A; Longo A; Mercurio C; Panzeri A; Pastori W; Pevarello P; Volpi D; Roussel P; Vulpetti A; Brasca MG
J Med Chem; 2010 Mar; 53(5):2171-87. PubMed ID: 20141146
[TBL] [Abstract][Full Text] [Related]
16. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
[TBL] [Abstract][Full Text] [Related]
17. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.
Rudolph D; Steegmaier M; Hoffmann M; Grauert M; Baum A; Quant J; Haslinger C; Garin-Chesa P; Adolf GR
Clin Cancer Res; 2009 May; 15(9):3094-102. PubMed ID: 19383823
[TBL] [Abstract][Full Text] [Related]
18. Identification of 2-anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as dual PLK1/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation.
Egert-Schmidt AM; Dreher J; Dunkel U; Kohfeld S; Preu L; Weber H; Ehlert JE; Mutschler B; Totzke F; Schächtele C; Kubbutat MH; Baumann K; Kunick C
J Med Chem; 2010 Mar; 53(6):2433-42. PubMed ID: 20170163
[TBL] [Abstract][Full Text] [Related]
19. A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis.
Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
Chembiochem; 2009 May; 10(7):1145-8. PubMed ID: 19350612
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905).
Duffey MO; Vos TJ; Adams R; Alley J; Anthony J; Barrett C; Bharathan I; Bowman D; Bump NJ; Chau R; Cullis C; Driscoll DL; Elder A; Forsyth N; Frazer J; Guo J; Guo L; Hyer ML; Janowick D; Kulkarni B; Lai SJ; Lasky K; Li G; Li J; Liao D; Little J; Peng B; Qian MG; Reynolds DJ; Rezaei M; Scott MP; Sells TB; Shinde V; Shi QJ; Sintchak MD; Soucy F; Sprott KT; Stroud SG; Nestor M; Visiers I; Weatherhead G; Ye Y; D'Amore N
J Med Chem; 2012 Jan; 55(1):197-208. PubMed ID: 22070629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
